Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Usnoflast - Zydus Cadila

Next Previous
Drug Profile

Usnoflast - Zydus Cadila

Alternative Names: NLRP3 inflammasome inhibitor - Zydus Cadila; ZYIL-1

Latest Information Update: 26 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zydus Cadila
  • Developer Zydus Cadila; Zydus Lifesciences
  • Class Anti-inflammatories; Antiparkinsonians; Small molecules
  • Mechanism of Action NLRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryopyrin-associated periodic syndromes; Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Cryopyrin-associated periodic syndromes; Parkinson's disease
  • Phase I Ulcerative colitis

Most Recent Events

  • 28 May 2025 Zydus Cadila receives Fast Track designation for Amyotrophic lateral sclerosis [PO,Capsule] in USA
  • 30 Jan 2025 Phase-II clinical trials in Parkinson's disease (PO) prior to January 2025 (Zydus Lifesciences pipeline; January 2025)
  • 30 Jan 2025 Usnoflast - Zydus Cadila receives Coronavirus Treatment Acceleration Program (CTAP) status for Cryopyrin-associated periodic syndromes in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top